Abstract:Anqi Lin, 1, &ast Jiarong Yao, 1, &ast Quan Cheng, 2, 3 Zaoqu Liu, 4 Peng Luo, 1 Jian Zhang 1 1 Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China; 2 Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 3 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 4 Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Peng Luo; Jian Zhang, Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China, Tel +86-18588447321 ; +86-13925091863, Email ; Purpose: In recent years, tumour immunotherapy has ushered in a new era of oncology treatment. However, the use of immune checkpoint inhibitors (ICIs) in the treatment of CRC remains limited. There is an urgent clinical need for precise biomarkers that can aid in the screening and treatment of CRC subtypes. Therefore, we focused on the NOTCH pathway mutation status and conducted a systematic analysis for its predictive value of ICI therapy efficacy. Methods: We collected mutational and clinical data from cohorts of CRC patients treated with ICIs. The relationship between NOTCH pathway mutations (NOTCH-MT) and CRC immunotherapy prognosis was analysed using univariate and multivariate Cox regression models. CRC cohort data from The Cancer Genome Atlas (TCGA) database were combined to obtain a comprehensive overview of immunogenicity and tumour microenvironment (TME) differences among different NOTCH pathway mutation statuses. Results: We observed greater infiltration of M1 macrophages, CD8+ T cells, neutrophils, and activated natural killer (NK) cells with NOTCH-MT status. Immunogenicity was also significantly higher in patients with NOTCH-MT, as were tumour mutational burden (TMB), neoantigen load (NAL), and the number of mutations in DNA damage repair (DDR) pathways. Conclusion: NOTCH-MT status was strongly associated with the prognosis of CRC patients treated with ICIs and is expected to serve as a novel biomarker and therapeutic target for CRC. Keywords: NOTCH, CRC, ICIs, biomarker, tumour microenvironment Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men worldwide and the second leading cause of cancer death. 1 Approximately 41% of CRC cases occur in the proximal colon, 22% in the distal colon, and 28% in the rectum. 2,3 Notably, 50% of patients develop distant metastasis, referred to as metastatic CRC (mCRC), which has a high mortality rate. Usually, chemoradiotherapy can be used to treat locally advanced CRC before surgery. However, some studies have shown that fractional radiation of tumour cells also leads to chemoresistance. 4,5 Therefore, new effective treatment strategies for advanced CRC patients are urgently needed. Immunotherapy, a treatment option that employs the body's immune system to fight cancer, has shown promise in treating certain cancer types. 6 While patients with some cancers, such as melanoma 7 and lung cancer, 8 benefit from immune checkpoint inhibitor (ICI)treatment, others do not. Recently, it was discovered that ICIs are effective in a subgroup of CRC patients with mismatch repair defect (dMMR) and high microsatellite instability (MSI-H) tumours (dMMR-MSI-H tumours) but are ineffective in another subgroup of patients with pMMR and low microsatellite instability (pMMR-MSI-L tumour). 9 The results indicated that patients with dMMR-MSI-H tumours had a 40% objective response rate when treated with pembrolizumab, compared to 0% in patients with pMMR-MSI-L tumors and a 78% immune-related progression-free survival rate when treated with pembrolizumab. 10 In addition, previous studies show that carcinoembryonic antigen (CEA) levels can predict prognosis in CRC patients. 11 However, elevated CEA levels have also been observed in many nonmalignant conditions, such as alcoholism, cigarette smoking, pancreatitis, and liver disease. 12 Therefore, it is critical to identify biomarkers with a high specificity and detection rates for predicting PD-1/PD-L1 ICI efficacy in patients with CRC. Important predictive molecular markers for ICI treatment of CRC include d-MMR-MSI-H, tumour mutational burden (TMB), tumour microenvironment (TME), tumour-infiltrating lymphocytes -Abstract Truncated-

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer

Snail/CXCL-8 Axis Promotes Expression of the Novel Surface Marker CD58 and Self-Renewal of Tumor-Initiating Cells in Colorectal Cancer

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC

Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer

Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer

B Cell Receptor Signaling Pathway Mutation As Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer

Mutations in the Notch Signalling Pathway Are Associated with Enhanced Anti‐tumour Immunity in Colorectal Cancer

Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer

Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer

Identification of Immune Cell Infiltration Landscape for Predicting Prognosis of Colorectal Cancer.

Analysis of Immune-Related Signatures of Colorectal Cancer Identifying Two Different Immune Phenotypes: Evidence for Immune Checkpoint Inhibitor Therapy.

Notch Pathway Defines an Aggressive and Immune-Suppressive Phenotype Associated with Checkpoint Inhibitor Resistance in Pan-Gastrointestinal Adenocarcinomas

Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma

Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer

Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.

A Mutational Signature That Predicts Prognosis and Benefit of Immune Checkpoint Blockade in Colorectal Cancer

Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer

The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry

Effect of TP53 Mutation on Antitumor Immunity and Responsiveness to Immunotherapy in Colorectal Cancer.